glp-1 news today 2025-10-16 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Perspectives from employers on the
Description
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
W., Swearengin, K., York, A
Overall, JM appears to be in good metabolic control
,
The evidence, however, does not strongly support this approach
cardiovascular and metabolic benefits remain areas of active study and product-specific safety information
